Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have emerged as standout performers for dividend-seeking investors. As of October 15, 2025, these companies represent compelling examples of
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which saw markets grappling with fresh developments in the ongoing U.S.-China trade saga. Despite earlier indications of a rebound with
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market attention.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency across critical industries. This new AI tool has made checking the quality of materials significantly easier, with profound and immediate implications for sectors such
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations legislation for the 2026 fiscal year. This eleventh government shutdown in U.S. history is sending ripples of
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Pfizer's Tukysa improved progression-free survival in first-line HER2+ metastatic breast cancer, showing strong efficacy and a manageable safety profile.
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy-based induction. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in the TUKYSA arm versus the placebo arm. Treatment with TUKYSA in combination with trastuzumab and pertuzumab was tolerable, with a safety profile generally consistent with the established safety profiles of each individual therapy.
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Shares of healthcare services provider BrightSpring Health Services (NASDAQ:BTSG)
jumped 3.3% in the afternoon session after several analysts signaled increased confidence in the company, with UBS being the latest to raise its price target. The bank maintained its "Buy" rating on the stock while lifting its price target to $35 from $31. This move was part of a broader trend of positive sentiment, following recent price target increases from firms including Wells Fargo and B of A Securities.
Adding to the optimism, analysts at TD Cowen, who also maintained a "Buy" rating, pointed to fundamental strength within the company. They highlighted expectations for strong results from BrightSpring's Pharmacy segment, helped by increased activity in certain generic drugs and new contracts for limited distribution drugs.
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data
Washington D.C., October 10, 2025 – The highly anticipated 2026 Social Security Cost-of-Living Adjustment (COLA) announcement, a critical financial marker for nearly 74 million Americans, faced significant headwinds and widespread doubt in early October due to an ongoing federal government shutdown. The disruption threatened to delay the release of vital
